Title: Clinical Trials
1Clinical Trials
- Jame Abraham, M.D
- Associate Professor of Medicine
- Chief, Section of Hematology-Oncology
2R word of academic medicine was
Research
3R word of academic medicine is
RVU
4Clinical Trials Definition
The NIH defines a clinical trial as a prospective
biomedical or behavioral research study of human
subjects that is designed to answer specific
questions about biomedical or behavioral
interventions (drugs, treatments, devices, or
new ways of using known drugs, treatments, or
devices).
Web site www.Grants.nih.gov/grants/funding/phs398
5A treatise of the scurvy James Lind 1753
61990 - 5000 pharmacists and physicians
conducted clinical trials of a new
drug 2000- More than 60,000 medical
professionals are principal investigators
7Types of clinical Trials
- Phase I/II/III clinical Trial
- Behavioral medicine study
- Study of a new procedure
- Trial of new devices
8Phase I Clinical Trial
- Phase I clinical trials test a new biomedical
intervention in a small group of people (e.g.,
20-80) for the first time to evaluate safety
(e.g., to determine a safe dosage range and to
identify side effects).
NIH definition
9- Phase I Trial and Pharmacokinetic Study of
BMS-247550, an Epothilone B Analog, Administered
Intravenously on a Daily Schedule for Five Days -
- Jame Abraham, Manish Agrawal, Susan Bakke, Ann
Rutt, Maureen Edgerly, Frank M. Balis, Brigitte
Widemann, Louis Davis, Bharat Damle, Daryl
Sonnichsen, David Lebwohl, Susan Bates, Herb
Kotz, and Tito Fojo - National Cancer Institute, Bethesda, MD
- JCO May 1 2003 1866-1873.
10Phase II Clinical Trial
- Phase II clinical trials study the biomedical or
behavioral intervention in a larger group of
people (several hundred) to determine efficacy
and to further evaluate its safety.
11- Phase II Clinical Trial of Ixabepilone
(BMS-247550), an Epothilone B Analog, in
Metastatic and Locally Advanced Breast Cancer - Jennifer A. Low, Suparna B. Wedam, James J. Lee,
Arlene W. Berman, Adam Brufsky, Sherry X. Yang,
Marianne S. Poruchynsky, Seth M. Steinberg, Nitin
Mannan, Tito Fojo, Sandra M. Swain - National Cancer Institute
- JCO Apr 20 2005 2726-2734.
12Phase III trials
- Phase III studies investigate the efficacy of the
biomedical or behavioral intervention in large
groups of human subjects (from several hundred to
several thousand) by comparing the intervention
to other standard or experimental interventions
as well as to monitor adverse effects, and to
collect information that will allow the
intervention to be used safely.
13- Ixabepilone Plus Capecitabine for Metastatic
Breast Cancer Progressing After Anthracycline and
Taxane Treatment - Eva S. Thomas, Henry L. Gomez, Rubi K. Li,
Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan,
Jacek Jassem, Xavier B. Pivot, Judith V.
Klimovsky, Fernando Hurtado de Mendoza, Binghe
Xu, Mario Campone, Guillermo L. Lerzo, Ronald A.
Peck, Pralay Mukhopadhyay, Linda T. Vahdat, Henri
H. Roché - JCO Nov 20 2007 5210-5217.
14International study with 752 Patients
15- From the M.D. Anderson, Houston, TX Instituto
Nacional de Enfermedades Neoplasicas Lima, Peru
Veterans Memorial Medical Center, Quezon City,
Philippines Yonsei Cancer Center, Seoul,
Republic of Korea Centro de Oncologia Rosario,
Sante Fe Hospital de Oncologia Maria Curie,
Buenos Aires, Argentina Medical University of
Gdansk, Gdansk, Poland C.H.U.Institut Claudius
Regaud, Toulouse, France Rajive Gandhi Instiute,
New Delhi, India, Cancer Hospital Chinese
Academy of Medical Sciences, Beijing, China and
Weill Medical College of Cornell University, New
York, NY
16Oncology Drug Approval Process
17FDA Approval for Ixabepilone Brand name
Ixempra On October 16, 2007, the U.S. Food and
Drug Administration (FDA) approved ixabepilone
for injection (Ixempra, made by Bristol-Myers
Squibb)
18Drug discovery can cost up to 800 million to a
billion dollars !
194,500 dollars for one infusion of Ixempra!!
Ixabepilone A Novel Microtubule Stabilizing
agent Expert Reviews in Oncology ( in
press) Gerald Higa and Jame Abraham
20Phase IV trial
- Phase IV studies are conducted after the
intervention has been marketed. These studies are
designed to monitor effectiveness of the approved
intervention in the general population and to
collect information about any adverse effects
associated with widespread use
21- Cardiovascular Events Associated with Rofecoxib
in a Colorectal Adenoma Chemoprevention Trial - Robert S. Bresalier, M.D., Robert S. Sandler,
M.D., Hui Quan, Ph.D., James A. Bolognese,
M.Stat., Bettina Oxenius, M.D., Kevin Horgan,
M.D., Christopher Lines, Ph.D., Robert Riddell,
M.D., Dion Morton, M.D., Angel Lanas, M.D.,
Marvin A. Konstam, M.D., John A. Baron, M.D., for
the Adenomatous Polyp Prevention on Vioxx
(APPROVe) Trial Investigators
Volume 3521092-1102 March 17, 2005 Number 11
22(No Transcript)
23Why Clinical Trials?
24- SCIENTIFIC MISCONDUCTCancer Researcher Sacked
for Alleged Fraud - Michael Hagmann
- Science 17 March 2000Vol. 287. no. 5460, pp.
1901 - 1902
- Conventional-Dose Chemotherapy Compared with
High-Dose Chemotherapy plus Autologous
Hematopoietic Stem-Cell Transplantation for
Metastatic Breast Cancer - Edward A. Stadtmauer, M.D., Anne O'Neill, M.S.,
NEJM, Volume 3421069-1076 April 13, 2000 Number
15
25Investigator Initiated Clinical Trials
26Investigator initiated studies
- Choosing a Research Question
- Protocol Development
- Writing a grant
- Clinical Protocol and Institutional
- Review Board
- Execution of the clinical Research
27Claude Bernard (1813-1878)
The first requirementin practicing experimental
medicine, is to be an observing physician and to
start from pure and simple observations of
patients made as completely as possible.
An Introduction to the Study of Experimental
Medicine 1865. He is considered as the "Father
of Physiology.
28Can chemotherapy affect my memory?
29(No Transcript)
30Epo receptors in the CNS
31Erythropoietin inhibits apoptosis
32Cognitive impairment is a problem in patients
receiving Chemotherapy Erythropoietin may be an
effective treatment!!
Excellent question!! Valid pre-clinical Model
33Selling points?
- Is it a novel idea?
- What is the relevance of the study?
- Is it a high priority study?
34Objectives of the study
In patients receiving adjuvant chemotherapy for
breast cancer
- 1. To study the Patho-physiology of cognitive
dysfunction Using 15O Water PET Scan - 2. Evaluate the effectiveness of the
erythropoietin using 15O Water PET scan
35Investigator initiated studies
- Choosing a Research Question
- Protocol Development
- Writing a grant
- Clinical Protocol and Institutional
- Review Board
- Execution of the clinical Research
36Protocol development
- Collaboration
- Design the study
- Statistician
- Writing the proposal
37Naresh Gupta, M.D Nuclear Medicine Marc Haut,
Ph.D Behavioural Medicine Hiroto Kuwabara, M.D,
PhD Johns Hopkins Joyce Oshaughnessy M.D Texas
Oncology
38Anterior peaks
Solvent exposed
Control subjects
z -5 z 26
z 21
z 23
Posterior peaks
z 47 z 52
z 40
z 52
39Study development
- Collaboration
- Design the study
- Statistician
- Writing the proposal
40Procrit
Double blinded
Randomized
12 patients
AC X 4 cycles
Prospective
PET scan NPT
24 patients
12 patients
AC X 4 cycles
PET scan NPT
Placebo controlled
Placebo
Schema of the study
41Study development
- Collaboration
- Design the study
- Statistician
- Writing the proposal
42Study development
- Collaboration
- Design the study
- Statistician
- Writing the proposal
43Investigator initiated studies
- Choosing a Research Question
- Protocol Development
- Writing a grant
- Clinical Protocol and Institutional
- Review Board
- Execution of the clinical Research
44Grant sources
- http//grants1.nih.gov/grants/index.cfm
- http//cdmrp.army.mil/
45Grant writing
- Scientific part
- Budget
- Ms. Elsa Nadler
46Office of the sponsored program (OSP)
47Investigator initiated studies
- Choosing a Research Question
- Protocol Development
- Writing a grant
- Clinical Protocol and Institutional
- Review Board
- Execution of the clinical Research
48Clinical Protocol
49Clinical Trials Research Unit
http//www.hsc.wvu.edu/mbrcc/ctru/
50Scientific Protocol Review Committee (Protocol
Review and Monitoring Committee PRMC)
51Institutional Review Board
Patient safety
Improving Protection for Research SubjectsRobert
Steinbrook, M.D. Volume 3461425-1430 May 2, 2002
New England Journal of Medicine
52Johns Hopkins Admits Fault in Fatal Experiment
''Regardless of the fact that we are unlikely
ever to know precisely how or why this happened,
Hopkins takes full responsibility for what did
happen,'' Dr. Edward B. Miller, the dean and
chief executive of Johns Hopkins Medicine
July 17 2001
53Investigator initiated studies
- Choosing a Research Question
- Protocol Development
- Writing a grant
- Clinical Protocol and Institutional
- Review Board
- Execution of the clinical Research
54- Erythropoietin, the FDA, and Oncology
- Robert Steinbrook, M.D.
- Volume 3562448-2451 June 14, 2007
55Abraham et al. Clinical Breast Cancer, Feb 2008
56Cognitive impairment in rats receiving
chemotherapy
Konat et. al Metabolic Brain Disease, Accepted
for Publication
57Research Team Principal Investigator Co-Investiga
tors Research Nurse Statistician Pharmacist Data
Manager Accountant Collaborators
58Clinical Trials Unit Shannon Filburn Rebecca
Keller Leah Darr Angela Price Christen Tringes
Cathy Patriarca Gerry Hobbs- Statistician
Marc Haut Greg Konat William Petros Aasim
Sehbai Maria Moran Cliff Martin
59Execution of Clinical Trial
- Patient recruitment
- Follow the protocol
- Be scientific and objective
- Maintain a highly ethical approach
60Research
RVU
61Conflict of Interest
- DOD Funding- 325,000 dollar
- Ortho Biotech- 425,000 dollars
- AstraZeneca 110,000 dollars (not active)
- Co-operative Groups
- NSABP
- ECOG
- Other Pharma
- Pfizer
- Eli Lilly
62Frequency of Various Types of Physician-Industry
Relationships
Campbell E. N Engl J Med 20073571796-1797
63 Conflict of Interest or Conflict of
Priorities? Elizabeth G. Nabel, M.D.
Volume 3552365-2367 November 30, 2006
64Investigator initiated studies
- Choosing a Research Question
- Protocol Development
- Writing a grant
- Clinical Protocol and Institutional
- Review Board
- Execution of the clinical Research
65But why think, why not try the
experiment? John Hunter, 1775
66Thank you!!